In case you were wondering, this is not the same swine flu of three-plus decades ago, according to MSNBC. If you had that vaccine – or even your annual flu shot just months ago – you should not consider yourself immune. Check the MSNBC story for for more FAQs on the swine flu. 

Video & screenshot, Fandome Dude

Post from: Blisstree

Swine Flu PSA – 1970s Revisited?

BioCurex

With the said test, scientists at BioCurex can differentiate cancer cells from healthy cells in ways that previous scientists have been unable to do.

According to Dr. Moro-Vidal, BioCurex’s President and CEO:

“Cancer markers help distinguish cancer cells from non-cancerous cells. The ideal marker is a molecule that’s present in all cancer cells of all tissue types — none of the present markers can do that; and RECAF is the only one discovered to date that comes very close to that ideal.”

Cancer markers are actually molecules found in human cells that identify certain cellular characteristics.

By notating whether markers are present or not, scientists are able to determine whether a cell is normal, benign, or cancerous.

The best cancer markers to date (AFP, CEA, PSA, and Ca125) have been in many ways effective in identifying cancer. BUT, these tests are limited by their ability to identify cancer only in certain organs.

RECAF, on the other hand, works across the board, showing very high sensitivity and specificity in all cancers so far studied, including lung, breast, prostate, ovarian, cervical, colorectal, stomach and others. These types represent the vast majority of all cancers.

BioCurex presented its results on blood testing for cancer detection at the annual meeting of the International Society for Oncofetal Biology and Medicine, which revealed that the company’s RECAF™ test detected twice the amount of cancer than PSA.

Read the full press release.

Post from: Blisstree

BioCurex’s Novel Test Using Their Patented RECAF™ Technology, May Detect Cancer Earlier, Surpassing Other Tests Available

The Purdue team has identified the protein, tumor-associated NADH oxidase (or tNOX), as a pan-cancer marker. The protein is critical to the ability of the tumor cell to grow and to survive.

They also have shown that there are different forms of this protein, known as isoforms, and that different tNOX isoforms are associated with different forms of cancer.

The team has demonstrated previously that tNOX is the primary molecular target for phenoxodiol. The 75 alpha protein appears to be the particular tNOX isoform found in prostate cancer patients, and that is one of the isoforms targeted by phenoxodiol.

Prostate cancer is one of the most serious and common types of cancer found in American men and we already know that prostate specific antigen (PSA) is another protein found exclusively on prostate cancer cells. While PSA is widely used to diagnose prostate cancer and to determine response to therapy, there is no anti-cancer drug that specifically targets PSA because the protein is not essential to tumor cell survival.

Therefore, PSA is not a universally reliable marker of the efficacy of a particular drug.

Because tNOX is essential for tumor cell survival, it makes for an excellent target for anti-cancer drug activity.

When phenoxodiol binds to tNOX, the protein is inhibited, blocking the cell from dividing, and switching off a variety of pro-survival signaling mechanisms within the cell. Where this inhibition reaches a certain level, the cell dies; where it is below a lethal level, the cell is blocked from dividing.

Marshall Edwards, Inc., (Nasdaq: MSHL) is the company developing phenoxodiol and has licensed rights to bring phenoxodiol to market globally from its parent company, Novogen Limited (ASX: NRT, Nasdaq: NVGN).

Results of the abovementioned trial (which involved 19 patients with late-stage, hormone- refractory prostate cancer) were presented September 15 at the International Conference on Molecular Diagnostics in Cancer Therapeutics (held September 12th to the 15th by the American Association of Cancer Research).

Read the full press release from Novogen.

Post from: Blisstree

Preliminary Study Revealed Evidence That Investigational Drug Phenoxodiol Targets Prostate Cancer Protein